News Hub | News Direct


Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Genflow Biosciences advances three major programs in fight against ageing diseases

Genflow Biosciences PLC

Genflow Biosciences PLC CE Dr Eric Leire tells Proactive's Stephen Gunnion the company had a successful year in 2023, allowing it to expand its research and development pipeline. Leire highlighted three main programs during an interview. The first focuses on MASH (Metabolic Dysfunction-Associated Steatohepatitis), soon progressing to clinical trials, indicating a strong move towards addressing liver diseases. The second program deals with Werner Syndrome, a progeria-related condition, where Genflow is innovating with synthetic organoids to mimic human organ function for better clinical trial predictions. The third program targets sarcopenia in collaboration with Revatis SA, aiming to combat muscle loss associated with ageing. The company has also engaged with regulatory agencies in Europe and the US, receiving positive feedback on its approach, particularly with its MASH program. It is awaiting further feedback from the FDA to decide the trial's location. In addition to a recent £715,000 fundraise, Genflow's financial strategy relies heavily on grants, with recent significant funding from the Wallonia Region in Belgium, which Leire believes positions it well to continue its work without heavy reliance on venture capital. Contact Details Proactive UK Ltd +44 20 7989 0813

May 09, 2024 07:37 AM Eastern Daylight Time

Article thumbnail News Release

Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones

Immunic Inc

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Vitt said the quarter was notable for Immunic's successful fundraising efforts, raising up to $240 million in a three-tranche private placement aimed at furthering its Multiple Sclerosis (MS) and gastrointestinal treatments. He also highlighted the importance of the recent allowance of a fourth US patent for vidofludimus calcium, enhancing its intellectual property portfolio around MS treatments and ensuring long-term commercial exclusivity. Vitt gave an update on the status of ongoing clinical trials, including the advanced Phase 2 CALLIPER trial for MS, with significant results expected in April next year. Moreover, he touched on Immunic's gastrointestinal disorder programs, particularly for celiac disease, with the IMU-856 program showing promising results in restoring gut wall functions. The interview also covered upcoming milestones, focusing on executing current clinical trials and preparing for future phases. Contact Details Proactive North America +1 604-688-8158

May 09, 2024 06:58 AM Eastern Daylight Time

Article thumbnail News Release

One Health Group sets another record for new patients choosing One Health through Patient Choice

One Health Group PLC

One Health Group PLC (AQSE:OHGR) CEO Adam Binns joined Proactive's Stephen Gunnion with details of a full-year trading update that showed revenue of more than £23 million for the year to 31 March 2024, and net year-end cash of £4.7 million, which will fund investment in future growth and underpin its progressive dividend policy. Binns explained that One Health Group operates as an independent provider of NHS services in the UK, specifically targeting various local economies with subcontracted health services. The company, established 22 years ago, focuses on providing non-surgical treatments and surgical interventions through subcontracted consultants and facilities. He emphasised patient choice, enabling patients to select their healthcare provider through GP referrals or directly from NHS waiting lists. One Health Group also boasts a rapid treatment timeline of 6 to 8 weeks compared to traditional NHS routes. Strategically, One Health Group is expanding its geographical footprint across the UK, moving into regions like Manchester and Coventry, with plans to increase their owned capacity for more efficient service delivery. Additionally, it secured two new five-year contracts with the NHS, reflecting confidence in its service quality and operational stability. Overall, One Health Group's model of integrating NHS and subcontracted services aims to alleviate pressure on NHS resources while maintaining high standards of patient care and operational efficiency. Contact Details Proactive UK Proactive UK +44 20 7989 0813

May 09, 2024 06:48 AM Eastern Daylight Time

Article thumbnail News Release

Fusion Antibodies reports second-half rebound as new commercial strategy pays off

Fusion Antibodies PLC

Fusion Antibodies PLC (AIM:FAB) CEO Adrian Kinkaid joined Proactive's Stephen Gunnion with more on the company that specialises in various stages of antibody development, excluding GMP production for clinical trials. He described Fusion Antibodies as a collaborative research organisation that engages deeply with clients to develop therapeutic antibodies, one of the most complex scientific endeavours. Its client base includes small VC-funded biotechs and has expanded to include large organisations like the National Cancer Institute. Fusion Antibodies also explores adjacent markets such as diagnostics, family medicine, and veterinary medicine. Recently, the company faced economic challenges, particularly a decrease in venture capital for biotechs, impacting its core business. However, it responded with strategic diversifications and cost management, leading to a 47% increase in fourth-quarter 2024 sales compared to the first quarter. The order pipeline at the year's end was significantly stronger at £750,000, promising a solid foundation for future growth. Kinkaid noted that Fusion Antibodies has secured various agreements, including a notable collaboration with the National Cancer Institute to employ their OptiMAL technology platform for discovering human antibodies. This platform could potentially lead to multiple licensing opportunities due to its vast diversity. Additionally, the company raised about £1.37 million, which will fund growth initiatives, including expanding its commercial team to better reach its primary market in the USA. Contact Details Proactive UK Proactive UK +44 20 7989 0813

May 09, 2024 06:41 AM Eastern Daylight Time

Article thumbnail News Release

Cloud DX secures 4th Provincial Health contract for remote patient monitoring

Cloud DX

Robert Kaul, CEO of Cloud DX, discussed with Steve Darling from Proactive the new Remote Patient Monitoring Agreement for Cloud DX RPM Services, which has been secured with a Canadian Provincial Health Authority. This agreement expands Cloud DX's provision of Connected Health remote patient monitoring products and services across Canada, now including contracts with Alberta, Yukon, Prince Edward Island, and a Master Services Agreement with Mohawk Medbuy—the country's largest hospital procurement agency. Kaul shared with Proactive that the contract spans 36 months and includes options for two 12-month extensions. Each subscription under these contracts is projected to average $1,520 CAD annually, covering the costs associated with the Connected Health Kit, which includes patient-prescribed hardware, software, and connectivity solutions. Over the four months leading up to April 30, 2024, Cloud DX has announced a significant growth milestone, securing 26 new contracts. These agreements span across hospitals, paramedic services, U.S. clinics, and include two Canadian provinces, marking a significant inflection point in the company’s expansion and presence in the healthcare industry. Contact Details Proactive North America +1 604-688-8158

May 08, 2024 02:48 PM Eastern Daylight Time

Article thumbnail News Release

Centre for Neuro Skills Promotes Dr. Omesh Singh to Associate Chief Medical Officer

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, today announced the promotion of Dr. Omesh Singh, D.O. FACOI, to associate chief medical officer. “Dr. Singh’s extensive knowledge and expertise has been a major asset to us. I’m excited to work in lockstep with him to deliver on our promise to give patients the best rehabilitative care science can offer,” said Dr. Matthew Ashley, chief medical officer of Centre for Neuro Skills. Since joining CNS in 2015, Singh has served as medical director overseeing CNS’ Dallas and Fort Worth clinics. A specialist in internal medicine and post-stroke treatment, Singh treats a wide range of patients recovering from traumatic and acquired brain injury. As associate chief medical officer, Singh will retain his current responsibilities and his oversight will expand from two to all seven clinics. Singh will report directly to Dr. Matthew Ashley, working closely to treat complex cases, oversee the standard of care and manage all medical operations. Singh received his Doctor of Osteopathic Medicine degree from the Lake Erie College of Osteopathic Medicine. He is a certified Fellow of the American College of Osteopathic Internists. He completed his Internal Medicine Residency training at Plaza Medical Center (Medical City Fort Worth), where he is an associate professor of internal medicine. Singh has served as an internal medicine physician in the Dallas-Fort Worth Metroplex for nearly a decade. The CNS Dallas clinic is a state-of-the-art 40,000 sq. ft. rehabilitation facility located in Irving, Texas. The Fort Worth clinic also offers patient-centered rehabilitation through advanced technology and skilled therapists. CNS has two other clinics in Texas (Houston and Austin) and three California clinics in Bakersfield, San Francisco and Los Angeles. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit:, Facebook, X (formerly known as Twitter), LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 Company Website

May 08, 2024 08:00 AM Pacific Daylight Time

Article thumbnail News Release

Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. Contact Details Proactive UK Ltd +44 20 7989 0813

May 08, 2024 08:32 AM Eastern Daylight Time

Article thumbnail News Release

Faron Pharmaceuticals' new CEO Dr Juho Jalkanen sets bold vision for 2024

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN) new CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with his vision for the company. The founding member and former chief operating officer of Faron said one of his priorities is to meet with the US Food & Drug Administration earlier than planned in the hope of fast-tracking its lead drug, bexmarilimab, which has shown huge promise in treating a type of rare blood cancer. The move follows promising data from the phase I trials involving patients with myelodysplastic syndrome (MDS) who were unresponsive to a class of drugs called hypomethylating agents (HMAs). Jalkanen highlighted the company's ongoing phase 2 trial targeting relapsed refractory MDS, emphasising the strategic goal of securing non-dilutive funding and considering future mergers and acquisitions as the drug shows promise. Jalkanen also discussed the potential of the lead drug candidate in treating specific macrophage-driven cancers, indicating an optimistic outlook for the near term, including significant milestones expected in 2024. These milestones include more phase 2 data, expected by late May, and subsequent FDA feedback, pivotal for future planning. The CEO expressed confidence in the company's position and its appeal to investors, especially given the biotech sector's recovery from a period he referred to as a "nuclear winter." Contact Details Proactive UK Ltd +44 20 7989 0813

May 08, 2024 08:19 AM Eastern Daylight Time

Article thumbnail News Release

ANGLE announces second assay with AstraZeneca as it deepens relationship with pharma giant


ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. With a contract value of £550,000, the project is scheduled for completion in the first quarter of next year. Newland said the agreement is an extension of a prior arrangement to develop a methodology for detecting CTC micronuclei and will use ANGLE's innovative Parsortix system. Successful development of this AR assay is expected to bolster the use of the Parsortix system in clinical oncology, particularly for assessing the efficacy of prostate cancer therapies. The discussion also touched upon the potential benefits of this development for ANGLE, suggesting it might significantly enhance the company's operations and market position. Contact Details Proactive UK Ltd +44 20 7989 0813

May 08, 2024 08:12 AM Eastern Daylight Time

1 ... 34567 ... 277